3/11
10:27 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $272.00 to $280.00. They now have a "neutral" rating on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $272.00 to $280.00. They now have a "neutral" rating on the stock.
3/11
08:49 am
alny
WearOptimo Introduces World-Class Advisory Board to Further Advance Microwearable Sensor Technology for Precision Health Monitoring [Yahoo! Finance]
Low
Report
WearOptimo Introduces World-Class Advisory Board to Further Advance Microwearable Sensor Technology for Precision Health Monitoring [Yahoo! Finance]
3/11
08:00 am
alny
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
Medium
Report
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
3/6
07:08 pm
alny
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced [Yahoo! Finance]
Low
Report
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced [Yahoo! Finance]
3/5
07:43 am
alny
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary [Yahoo! Finance]
Low
Report
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary [Yahoo! Finance]
3/5
07:00 am
alny
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Low
Report
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
2/26
12:25 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
2/26
11:36 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
2/26
08:15 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
2/26
08:00 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
2/25
02:34 pm
alny
OXLUMO Continues Upward Market Momentum, Reinforcing RNAi Leadership in Primary Hyperoxaluria Treatment | DelveInsight [Yahoo! Finance]
Low
Report
OXLUMO Continues Upward Market Momentum, Reinforcing RNAi Leadership in Primary Hyperoxaluria Treatment | DelveInsight [Yahoo! Finance]
2/25
07:23 am
alny
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day [Yahoo! Finance]
Low
Report
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day [Yahoo! Finance]
2/25
07:00 am
alny
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
Low
Report
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
2/24
11:32 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $400.00 to $500.00. They now have a "buy" rating on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $400.00 to $500.00. They now have a "buy" rating on the stock.
2/20
07:17 pm
alny
Elevating Recognition at Scale: Espresa Introduces the Ultimate Global Rewards Marketplace [Yahoo! Finance]
Low
Report
Elevating Recognition at Scale: Espresa Introduces the Ultimate Global Rewards Marketplace [Yahoo! Finance]
2/18
08:00 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Canaccord Genuity Group Inc. from $384.00 to $385.00. They now have a "buy" rating on the stock.
Medium
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Canaccord Genuity Group Inc. from $384.00 to $385.00. They now have a "buy" rating on the stock.
2/14
01:29 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Scotiabank from $310.00 to $300.00. They now have a "sector outperform" rating on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Scotiabank from $310.00 to $300.00. They now have a "sector outperform" rating on the stock.
2/14
09:24 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $275.00 to $284.00. They now have an "equal weight" rating on the stock.
Medium
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $275.00 to $284.00. They now have an "equal weight" rating on the stock.
2/14
08:07 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Medium
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
2/13
07:07 pm
alny
Alnylam: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Alnylam: Q4 Earnings Snapshot [Yahoo! Finance]
2/13
05:05 pm
alny
https://seekingalpha.com/article/4758153-alnylam-waiting-for-regulatory-updates-in-march [Seeking Alpha]
Medium
Report
https://seekingalpha.com/article/4758153-alnylam-waiting-for-regulatory-updates-in-march [Seeking Alpha]
2/13
12:35 pm
alny
https://seekingalpha.com/article/4757990-alnylam-pharmaceuticals-inc-alny-q4-2024-earnings-call-transcript [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4757990-alnylam-pharmaceuticals-inc-alny-q4-2024-earnings-call-transcript [Seeking Alpha]
2/13
08:35 am
alny
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress [Yahoo! Finance]
Low
Report
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress [Yahoo! Finance]
2/13
08:00 am
alny
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Low
Report
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
2/13
07:44 am
alny
Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines [Yahoo! Finance]
Low
Report
Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines [Yahoo! Finance]